文献速递血管炎

巨细胞动脉炎患者糖皮质激素治疗相关结局的发生率

Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis.
PubMed 文献 · Semin Arthritis Rheum · 2016-10-13

基于英国临床实践研究数据链的回顾性随访研究,纳入5011例GCA患者与5011例按年龄、性别等匹配的非GCA患者,比较糖尿病、骨质疏松、骨折、青光眼、需住院严重感染及死亡的发生率。GCA组所有结局发生率均更高,骨质疏松(IRR 2.4)和青光眼(IRR 2.0)风险升高最明显,死亡风险仅边缘升高(IRR 1.2,95%CI 1.0-1.3)。

要点

  • GCA患者骨质疏松风险是非GCA匹配人群的2.4倍(IRR 2.4,95%CI 2.1-2.8)。
  • GCA患者青光眼风险为2.0倍,糖尿病和骨折风险均为1.4倍。
  • 需住院严重感染风险为1.5倍,死亡风险仅边缘升高(IRR 1.2,95%CI 1.0-1.3)。

核心结论

  • 与年龄和性别匹配的非GCA患者相比,GCA患者糖尿病、骨质疏松、骨折和青光眼风险增加,死亡风险仅边缘升高。

研究设计与样本

  • 回顾性随访研究,使用英国临床实践研究数据链数据,纳入5011例GCA患者和5011例按年龄、性别、全科诊所和日历时间匹配的非GCA患者。
  • GCA组纳入标准为50岁及以上首次诊断GCA且至少接受1次泼尼松龙处方。

主要发现

  • GCA组所有结局的发生率均高于非GCA组。
  • 糖尿病IRR为1.4(95%CI 1.2-1.7),骨质疏松IRR为2.4(95%CI 2.1-2.8),骨折IRR为1.4(95%CI 1.2-1.6)。
  • 青光眼IRR为2.0(95%CI 1.6-2.5),需住院严重感染IRR为1.5(95%CI 1.3-1.7),死亡IRR为1.2(95%CI 1.0-1.3)。

关键数值与推荐

  • GCA组约74%为女性,GCA诊断时平均年龄为72.9岁。

临床怎么用

  • 对GCA患者应关注糖皮质激素相关不良结局,包括糖尿病、骨质疏松、骨折、青光眼和严重感染。
  • GCA患者死亡风险仅边缘升高,临床可重点管理上述可干预并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Giant cell arteritis (GCA) is an inflammatory disorder of blood vessels that preferentially affects large- and medium-sized arteries. High-dose oral corticosteroids (CS) are the mainstay of GCA therapy. Using data from the UK Clinical Practice Research Datalink, we quantified and compared the incidence of selected potentially CS-associated adverse outcomes in patients with and without GCA. METHODS: We conducted a retrospective follow-up study of GCA and non-GCA patients to examine the incidence of adverse outcomes attributable to CS use. Eligibility criteria for the GCA group included a first-time diagnosis of GCA at age 50 years or older with receipt of ≥1 prescription(s) for prednisolone. GCA patients were matched to a GCA-free comparison group of equal size on age, sex, general practice, and calendar time. We estimated incidence rates and incidence rate ratios (IRRs) for diabetes, osteoporosis, glaucoma, fractures, serious infection requiring hospitalization, and death for GCA and non-GCA patients and compared all-cause hospitalizations between the two groups. RESULTS: The cohort consisted of 5011 GCA and 5011 matched non-GCA patients. Approximately 74% were women, and mean age at GCA diagnosis was 72.9 years. The IR for all outcomes was greater in the GCA group than the non-GCA group. IRRs [95% confidence intervals (CIs)] were as follows: diabetes 1.4 (1.2-1.7), osteoporosis 2.4 (2.1-2.8), fractures 1.4 (1.2-1.6), glaucoma 2.0 (1.6-2.5), serious infection requiring hospitalization 1.5 (1.3-1.7), and death 1.2 (1.0-1.3). CONCLUSION: Compared with age- and sex-matched non-GCA patients, patients with GCA were at increased risk for diabetes, osteoporosis, fracture, and glaucoma and at a marginally increased risk for death.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Wilson JC, Sarsour K, Collinson N, et al. Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis. Semin Arthritis Rheum. 2016. PMID: 27839741. doi:10.1016/j.semarthrit.2016.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。